Literature DB >> 25301140

Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study.

Daisuke Mizushima1, Junko Tanuma2, Nguyen Thi Dung3, Nguyen Hoai Dung3, Nguyen Vu Trung3, Nguyen Tien Lam3, Hiroyuki Gatanaga4, Yoshimi Kikuchi2, Nguyen Van Kinh3, Shinichi Oka4.   

Abstract

BACKGROUND: The use of tenofovir has been rapidly increasing in Vietnam. Several studies identified low body weight as a risk factor for tenofovir-induced nephrotoxicity. However, little is known about the impact of tenofovir on renal function in HIV-infected Vietnamese with generally low weight.
METHODS: An observational single-center cohort of adult HIV-infected patients on antiretroviral therapy at National Hospital of Tropical Diseases, Hanoi. Patients on tenofovir or with creatinine clearance ≤60 ml/min at baseline were excluded. The incidence of renal dysfunction was compared between patients who switched to tenofovir and those who did not. Renal dysfunction was defined as 25% decline of creatinine clearance from baseline. Time to renal dysfunction was analyzed by the Kaplan-Meier method between the two groups. The Cox hazard model was used to determine risk factors for renal dysfunction in uni- and multivariate analyses.
RESULTS: Of 556 patients enrolled in this study, 403 were non-tenofovir group while 153 were the tenofovir-switched group. Renal dysfunction occurred at a higher rate in the tenofovir-switched group (92.5 per 1000 person-years) than the non-tenofovir group (47.8 per 1000 person-years)(p = 0.023, Log-rank test). Multivariate analysis confirmed that tenofovir use, low body weight and glucosuria were significant risk factors for renal dysfunction (hazard ratio = 1.980; 95% confidential interval, 1.094-3.582, HR = 1.057; 95%CI, 1.016-1.098, HR = 5.202; 95%CI, 1.245-21.738, respectively).
CONCLUSIONS: Tenofovir use, low body weight and glucosuria were significant risk factors for renal dysfunction. We suggest close monitoring of renal function in patients with these risk factors even in resource-limited setting.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Human immunodeficiency virus; Low body weight; Renal dysfunction; Tenofovir; Vietnamese

Mesh:

Year:  2014        PMID: 25301140     DOI: 10.1016/j.jiac.2014.08.015

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  7 in total

1.  Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors.

Authors:  Geoffroy Liegeon; Linda Harrison; Anouar Nechba; Guttiga Halue; Sukit Banchongkit; Ampaipith Nilmanat; Naruepon Yutthakasemsunt; Panita Pathipvanich; Suchart Thongpaen; Rittha Lertkoonalak; Thomas Althaus; Marc Lallemant; Jean-Yves Mary; Gonzague Jourdain
Journal:  J Infect       Date:  2019-08-08       Impact factor: 6.072

2.  Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.

Authors:  Kyoung Hwa Lee; Ji Un Lee; Nam Su Ku; Su Jin Jeong; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

3.  Long-term clinical, immunological and virological outcomes of patients on antiretroviral therapy in southern Myanmar.

Authors:  Elkin Hernán Bermúdez-Aza; Sharmila Shetty; Janet Ousley; Nang Thu Thu Kyaw; Theint Thida Soe; Kyipyar Soe; Phyu Ei Mon; Kyaw Tin Tun; Iza Ciglenecki; Susanna Cristofani; Marcelo Fernandez
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

4.  Reduced Kidney Function in Tenofovir Disoproxil Fumarate Based Regimen and Associated Factors: A Hospital Based Prospective Observational Study in Ethiopian Patients.

Authors:  Taklo Simeneh Yazie; Teferra Abula Orjino; Wondwossen Amogne Degu
Journal:  Int J Nephrol       Date:  2019-02-03

5.  Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam.

Authors:  Cuong Q Hoang; Hai D Nguyen; Huy Q Vu; Khai T Nguyen; Linh T Hoang; Hong Ly; Thang D Tat; Lan T Phan
Journal:  Biomed Res Int       Date:  2020-01-10       Impact factor: 3.411

6.  Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.

Authors:  Nang Thu Thu Kyaw; Anthony D Harries; Palanivel Chinnakali; Annick Antierens; Kyi Pyar Soe; Mike Woodman; Mrinalini Das; Sharmila Shetty; Moe Khine Lwin Zuu; Pyae Sone Htwe; Marcelo Fernandez
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

7.  Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.

Authors:  Junko Tanuma; Awachana Jiamsakul; Abhimanyu Makane; Anchalee Avihingsanon; Oon Tek Ng; Sasisopin Kiertiburanakul; Romanee Chaiwarith; Nagalingeswaran Kumarasamy; Kinh Van Nguyen; Thuy Thanh Pham; Man Po Lee; Rossana Ditangco; Tuti Parwati Merati; Jun Yong Choi; Wing Wai Wong; Adeeba Kamarulzaman; Evy Yunihastuti; Benedict Lh Sim; Winai Ratanasuwan; Pacharee Kantipong; Fujie Zhang; Mahiran Mustafa; Vonthanak Saphonn; Sanjay Pujari; Annette H Sohn
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.